Novozymes Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Novozymes ha aumentado sus beneficios a una tasa media anual de 1.5%, mientras que los beneficios de la industria de Chemicals han experimentado un descenso de 2.5% anual. Los ingresos han ido creciendo a una tasa media de 5.4% al año. La rentabilidad financiera de Novozymes es de 21.2%, y sus márgenes netos son de 16.9%.

Información clave

1.5%

Tasa de crecimiento de los beneficios

2.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Chemicals	4.3%
Tasa de crecimiento de los ingresos	5.4%
Rentabilidad financiera	21.2%
Margen neto	16.9%
Próxima actualización de resultados	28 Aug 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Novozymes. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:0Q4U Ingresos, gastos y beneficios (DKK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	17,899	3,024	3,325	2,017
30 Sep 23	17,825	3,209	3,291	2,013
30 Jun 23	17,736	3,425	3,319	2,027
31 Mar 23	17,805	3,628	3,284	2,010
31 Dec 22	17,553	3,676	3,198	1,986
30 Sep 22	16,858	3,418	3,292	1,951
30 Jun 22	16,252	3,108	3,108	1,911
31 Mar 22	15,546	3,093	2,995	1,912
31 Dec 21	14,951	3,146	2,828	1,982
30 Sep 21	14,563	3,175	2,492	1,995
30 Jun 21	14,233	3,044	2,397	2,037
31 Mar 21	14,002	2,895	2,308	2,008
31 Dec 20	14,012	2,825	2,299	1,905
30 Sep 20	14,297	3,093	2,303	1,850
30 Jun 20	14,570	3,020	2,431	1,893
31 Mar 20	14,679	3,273	2,497	1,968
31 Dec 19	14,374	3,154	2,459	1,966
30 Sep 19	14,357	3,069	2,492	1,959
30 Jun 19	14,311	3,238	2,398	1,939
31 Mar 19	14,351	3,116	2,351	1,859
31 Dec 18	14,390	3,226	2,334	1,852
30 Sep 18	14,349	3,183	2,322	1,897
30 Jun 18	14,271	3,194	2,308	1,837
31 Mar 18	14,311	3,154	2,382	1,849
31 Dec 17	14,531	3,119	2,470	1,901
30 Sep 17	14,572	3,131	2,486	1,895
30 Jun 17	14,382	3,063	2,468	1,887
31 Mar 17	14,273	3,077	2,439	1,866
31 Dec 16	14,142	3,050	2,414	1,865
30 Sep 16	13,880	2,936	2,434	1,841
30 Jun 16	14,012	2,929	2,477	1,880
31 Mar 16	14,032	2,861	2,464	1,931
31 Dec 15	14,002	2,823	2,462	1,896
30 Sep 15	13,731	2,734	2,390	1,906
30 Jun 15	13,393	2,630	2,342	1,878
31 Mar 15	13,005	2,539	2,324	1,812
31 Dec 14	12,459	2,526	2,276	1,766
30 Sep 14	12,218	2,484	2,338	1,688
30 Jun 14	11,970	2,413	2,311	1,614
31 Mar 14	11,934	2,379	2,332	1,577
31 Dec 13	11,746	2,200	2,321	1,528
30 Sep 13	11,617	2,132	2,253	1,533
30 Jun 13	11,519	2,085	2,283	1,536

Ingresos de calidad: 0Q4U tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(16.9%) de 0Q4U son inferiores a los del año pasado (20.9%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 0Q4U han crecido un 1.5% al año en los últimos 5 años.

Acelerando crecimiento: 0Q4U ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 0Q4U tuvo un crecimiento negativo de los beneficios (-17.7%) durante el año pasado, lo que dificulta la comparación con la media de la industria Chemicals (-18.4%).

Novozymes Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Full year 2022 earnings released

Recent updates

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

New 90-day high: kr.383

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

New 90-day low: kr.338

Novozymes A/S Announces Executive Changes

New 90-day low: kr.357

Desglose de ingresos y gastos
Beta